Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 7/20 | 0.75 |
| ▸ | ABL1 | P00519 | 10/20 | 0.74 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.70 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.61 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.56 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.56 |
| ▸ | PI4KA | P42356 | 1/20 | 0.56 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1303127 | 0.90 | PIK3CG (0.72) | PIK3CGABL1PIK3CAPIK3CDPIP5K1C | |
| SCHEMBL1301924 | 0.87 | PIK3CG (0.68) | PIK3CGABL1PIK3CAPIK3CDPIP5K1C | |
| SCHEMBL1621705 | 0.86 | PIK3CG (1.00) | PIK3CGPIK3CAPIK3CDPIP5K1CPIK3CB | |
| SCHEMBL1303700 | 0.84 | PIK3CG (0.64) | PIK3CGABL1PIK3CARAB9A | |
| SCHEMBL6068368 | 0.81 | ABL1 (0.71) | PIK3CGABL1PIK3CAPIK3CDNPC1 | |
| SCHEMBL6068110 | 0.80 | ABL1 (0.80) | PIK3CGABL1PIK3CAPIK3CDNPC1 | |
| SCHEMBL1282877 | 0.80 | ABL1 (0.83) | PIK3CGABL1PIK3CANPC1RAB9A | |
| SCHEMBL1621895 | 0.80 | PIK3CG (0.80) | PIK3CGPIK3CAPIK3CDPIK3CBPI4KA | |
| SCHEMBL13188753 | 0.79 | PIK3CG (0.56) | PIK3CGABL1PIK3CAPIK3CDPIK3CB | |
| SCHEMBL1303474 | 0.79 | PIK3CG (0.56) | PIK3CGABL1PIK3CAPIK3CDPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8053574-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | claimed |
| US-20100197682-A1 | Organic Compounds | NOVARTIS AG | 2010-08-05 | — | — | US | claimed |
| EP-2178868-A1 | BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | Novartis Ag (CH) | 2010-04-28 | — | — | EP | claimed |
| WO-2009010530-A1 | BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-01-22 | — | — | WO | claimed |
| US-8053574-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | disclosed |
| US-20100197682-A1 | Organic Compounds | NOVARTIS AG | 2010-08-05 | — | — | US | disclosed |
| EP-2178868-A1 | BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | Novartis Ag (CH) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009010530-A1 | BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197682-A1 | Organic Compounds | PIK3CA, PI4KA, PI4KB | PIK3CG 11/4885ABL1 220/4885PIK3CA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.